Metrion Biosciences awarded £200k funding to further develop in-house drug discovery pipeline

6 Feb 2018

Funding will support further development of recently acquired small molecule assets for treatment of autoimmune disease.

Metrion Biosciences has been awarded £200k funding under the Innovate UK Biomedical Catalyst Feasibility Award scheme. The funding will be used to support further development of Metrion’s in-house drug discovery pipeline.

Metrion Biosciences awarded £200k funding to further develop in-house drug discovery pipeline

The funding will enable further preclinical development activities to be undertaken on the portfolio of small molecule potassium inhibitors acquired by Metrion from Japan Tobacco, with the aim of delivering a ‘best in class’, orally bioavailable, small molecule potassium channel inhibitor for the safe and effective treatment of a range of autoimmune diseases. This project is the first of a series of potassium channel inhibitor programmes Metrion has planned, which are designed to deliver proof of concept data on immune-sparing drug candidates, for treatment of autoimmune and neurodegenerative diseases.

Marc Rogers, Chief Scientific Officer, Metrion Biosciences, said: “We are pleased to receive this support from the Biomedical Catalyst scheme, which recognises Metrion’s contribution to R&D and drug discovery in the UK. Our team has extensive experience in the field of potassium ion channel drug discovery, having been responsible for discovery and development of three novel potassium channel therapeutics for the treatment of cardiac atrial fibrillation. We are excited to begin work on this project.”

Read More

Related news

Allergan to establish R&D presence in Cambridge, Massachusetts

Allergan to establish R&D presence in Cambridge, Massachusetts

10 Jan 2019

The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.

Read more 
Expedeon signs supply and license agreement for is Lightning-Link technology

Expedeon signs supply and license agreement for is Lightning-Link technology

9 Jan 2019

The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.

Read more 
WuXi AppTec expands site in California for pharmaceutical R&D services

WuXi AppTec expands site in California for pharmaceutical R&D services

13 Dec 2018

Expanded facility will establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including Phase I GMP manufacturing.

Read more 
Cambrex expands analytical capabilities

Cambrex expands analytical capabilities

12 Dec 2018

The $1 million investment will assist in getting new products to commercial launch faster.

Read more 
MIT engineers repurpose wasp venom as an antibiotic drug

MIT engineers repurpose wasp venom as an antibiotic drug

9 Dec 2018

Altered peptides from a South American wasp’s venom can kill bacteria but are nontoxic to human cells.

Read more 
Spanish CDMO working ahead of EU serialisation deadline

Spanish CDMO working ahead of EU serialisation deadline

6 Dec 2018

Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.

Read more 
Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases

5 Dec 2018

The financing will power the global commercial launch of the company's Fluidity One system.

Read more 
OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD

4 Dec 2018

The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.

Read more 
NIH to evaluate effectiveness of male contraceptive skin gel

NIH to evaluate effectiveness of male contraceptive skin gel

28 Nov 2018

The gel formulation includes the progestin compound segesterone acetate, in combination with testosterone, and is applied to the back and shoulders and absorbed through the skin.

Read more 
QPS expands US-based Phase I clinical trial capabilities

QPS expands US-based Phase I clinical trial capabilities

27 Nov 2018

Expansion supports the growing needs of the company's pharmaceutical, biotechnology and CRO partners.

Read more